Epigenetic Combination Therapy for Children With Secondary Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML) and Concurrent Solid Tumor Relapse.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Pediatric Hematology/Oncology"
DOI: 10.1097/mph.0000000000000868
Abstract: Secondary myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) is a rare but devastating complication of solid tumor treatment involving high-dose topoisomerase II inhibitor and alkylator chemotherapy. For relapsed or elderly MDS and AML patients ineligible for… read more here.
Keywords: solid tumor; myelodysplastic syndrome; therapy; mds ... See more keywords
Patient age and number of apheresis days may predict development of secondary myelodysplastic syndrome and acute myelogenous leukemia after high‐dose chemotherapy and autologous stem cell transplantation for lymphoma
Sign Up to like & getrecommendations! Published in 2017 at "Transfusion"
DOI: 10.1111/trf.14016
Abstract: The goal of our study was to find predictors for the development of secondary myelodysplastic syndrome or acute myelogenous leukemia (s‐MDS/AML) in patients with relapsed or refractory lymphoma who received high‐dose chemotherapy and autologous stem… read more here.
Keywords: development secondary; acute myelogenous; myelogenous leukemia; myelodysplastic syndrome ... See more keywords